Global Minimal Residual Disease Market Size Percentage Will Reach USD 7,131.61 Million By 2032, With CAGR of 13.7%: Polaris Market Research

NEW YORK, Jan. 26, 2023 /PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-User; By Region; Segment Forecast, 2023-2032" published by Polaris Market Research in its research repository.

According to the research study, the global minimal residual disease market size was valued at USD 1,973.35 million in 2022 and is expected to reach USD 7,131.61 Million By 2032, growing at a CAGR of 13.7% during the forecast period.

What is Minimal Residual Disease? What is the Size & Share of Minimal Residual Disease Market?

• Overview

Minimal residual disease is often used by physicians when treating patients with a blood cancer such as leukemia, lymphoma, or multiple myeloma. The cancer cells remaining after treatment cannot be detected by those same scans or tests. The rapidly rising demand for a minimal residual disease market can be attributed to the fact that much can be learned about what is left after the treatment. This can be done by adding medications that target particular vulnerabilities in the cancer cells, including medicines that effectively kill residual cells.

The rise in the number of patients with cancer is anticipated to drive market growth during the forecast period. The development of efficient and advanced technology and the growing government initiatives globally are the driving factors for market growth. Additionally, the rise in research and development activities, the increase in personalized medicines for treatments, and the surge in collaboration for product development are opportunities for market growth.

Request Sample Copy of Minimal Residual Disease Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Our Sample Report May Includes:

• 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
• 115+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Request.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
• Includes Updated List of table & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Key data covered in the market report

• Detailed overview of the parent market
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current, and projected market size in terms of volume and value
• Recent industry trends and development

Some of the Top Market Players Are:

• Sysmex Corporation
• ArcherDX
• Adaptive Biotechnologies
• Natera
• Inivata
• Asuragen
• Guardant Health
• Cergentis
• Invivoscribe
• Mission Bio
• ARUP Laboratories
• NeoGenomics Laboratories
• Bio-Rad Laboratories
• Opko Health
• Sysmex Corporation
• Quest Diagnostics

To know an additional revised list of top market players, request a sample report, 2023-2032: https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/request-for-sample

Key factors driving market growth

·  Growing consumer preference for tailored therapies to push the market

Growing incidences of hematological malignancies, growing consumer preference for tailored therapies, and growing prevalence of blood cell-related cancer across the globe are key factors driving market revenue growth. The minimal residual disease market size is expanding due to increasing approvals from US Food and Drug Administration for various treatment methods for MRD are also creating opportunities for the market to grow.

Prominent market companies are taking several initiatives to expand access, making it easier to utilize, collaborating with others, and innovating to shape the future of targeted therapy. Minimal residual disease market sales are soaring as companies invest extensively to build better and more patient-centric healthcare systems by empowering patients to take charge of their health, lowering costs, and increasing accessibility of genetic testing while empowering medical professionals to diagnose, treat, and prevent disease more effectively.

Directly Purchase a copy of report with TOC @ https://www.polarismarketresearch.com/checkouts/19731

Recent trends influencing the market

• There has been an exponential rise in the incidences of cancer globally, which is likely to play a pivotal role in the market expansion. Patients who are suffering from cancer and are going through cancer treatments are expected to reinforce the development of the market in the years to come.
• The ineptitude of polymerase chain reactions, FISH, and flow cytometry to quantify beyond 1 in every 100,000 cells is expected to shift the patient's attention toward the disease. With new technologies in treatments, patients are estimated to observe more accuracy in the treatment. These factors are likely to impact the growth of the market.

·  Segmentation assessment

• Leukaemia is predicted to dominate the industry's market segment

Based on the detection target, leukemia is predicted to dominate the industry's market segment. Minimal residual disease market demand is rising as one person in the US is diagnosed with leukemia every three minutes. For instance, as per the American Cancer Society, in 2022, there were around 60,650 new instances of leukemia, 24,000 people died from the disease, and about 20,050 new cases of acute myeloid leukemia were detected. Leukaemia's new possibilities were 14.1 per 100,000 men and women annually. The annual mortality rate was 6.0 per 100,000 men and women.

• The flow cytometry segment will dominate the market

Based on the test technique, the flow cytometry segment will dominate the market. This is due to the outstanding sensitivity and extensive applicability of MRD testing made possible by flow cytometry. The clinical care of individuals with acute leukemia places a growing emphasis on minimal residual disease testing. Minimal residual disease market trends include the technologies in monitoring MRD; flow cytometry has the most potential for clinical usage due to its ease of use and accessibility. Several investigations have underpinned the method's validity by demonstrating high relationships between MRD levels measured by flow cytometry during clinical remission and treatment results.

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/inquire-before-buying

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Minimal Residual Disease Market: Report Scope

Geographic Overview

• Rising healthcare affordability to drive the North American market

North America held the largest minimal residual disease market share due to rising healthcare affordability in the US. Due to the high level of patient and physician awareness of the benefits associated with screening, the US and Canada are the two main markets for cancer screening in North America. Further, several projects are being implemented to offer MRD testing in the area.

Browse the Detail Report "Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-User; By Region; Segment Forecast, 2023-2032" with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market   

For Additional Information OR Media Enquiry, Please Mail At: [email protected]

Polaris Market Research has segmented the Minimal Residual Disease Market report based on detection target, test technique, end-user, and region:

By Detection Target Outlook

• Lymphoma
• Leukemia
• Solid Tumors
• Others

By Test Technique Outlook

• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Others

By End User Outlook

• Hospitals and Specialty Clinics
• Laboratory Centres

By Region Outlook

• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Browse More Related Reports:

• Natamycin Market: https://www.polarismarketresearch.com/industry-analysis/natamycin-market
• Omics Lab Services Market: https://www.polarismarketresearch.com/industry-analysis/omics-lab-services-market
• Healthcare Bioconvergence Market: https://www.polarismarketresearch.com/industry-analysis/healthcare-bioconvergence-market
• Rabies Veterinary Vaccine Market: https://www.polarismarketresearch.com/industry-analysis/rabies-veterinary-vaccines-market
• Dendritic Cell Cancer Vaccine Market: https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Contact:

Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: [email protected]
Web: https://www.polarismarketresearch.com 
Follow Us: LinkedIn | twitter

Logo: https://mma.prnewswire.com/media/1316207/Polaris_Market_Research_Logo.jpg

SOURCE Polaris Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED